Healthcare companies face enormous challenges during this era of reform. The marketplace of the future will require new paradigms to realize the vision of affordability and quality. Change will impact payers, providers, and pharmaceutical companies alike and require unprecedented collaboration at the intersections.

Recognizing the power of a systemic view, healthcare companies are turning to Oliver Wyman. Our deep expertise across the healthcare landscape is centered in integrated health management – a differentiated approach in the marketplace that has been proven to drive critical transformation. Our perspective in life sciences is focused on transformational changes that pharmaceutical and biotechnology companies need to make in a world where product innovation is more challenging and where value is measured in patient outcomes.

Healthcare Reform

Oliver Wyman’s ground-breaking analysis of the House and Senate proposals informed the debate on healthcare reform and is now part of our analytic toolbox. We use scenario planning, strategic realignment, and transition management to help clients reposition themselves in a reform-driven market. 

Integrated Health Management (IHM)

Our IHM framework is a comprehensive, holistic approach to care management and delivery. With IHM, companies can compete on the cost and quality of care, achieving savings not by rationing care or cutting benefits but by coordinating care, correctly focusing resources, and aligning the interests of payers, patients, and healthcare providers. 

Strategic Growth Services

Oliver Wyman’s depth of knowledge and state-of-the-art analytics have helped healthcare organizations pick high-growth markets and build winning capabilities. We leverage our assets against the future marketplace, with a focus on competitive differentiation, shifts to retail, and strategic repositioning. 

Bio-Pharma Ecosystems

The end of the blockbuster era calls for a dramatic shift in thinking. Oliver Wyman has created a new strategic framework that maps the evolution of medicines markets, and how the various ‘ecosystems’ are becoming more different than similar. Our approach integrates disparate threads of science, commercialization, and clinical health value for a more cohesive and more sector-specific approach to strategy.

Reinventing R&D

Oliver Wyman's expertise and proven frameworks enable bio-pharma companies to advance fundamental transformations in R&D—challenging R&D rules of thumb more appropriate for yesterday’s portfolio, integrating the ‘health value’ frame in R&D processes, and defining product and portfolio strategies that fit the medical requirements of tomorrow.

Proving Economic Value

Payer influence is growing in today’s market, setting pharma up for a large paradigm shift. Oliver Wyman can help companies thrive in the healthcare environment of the future—where outcomes and value are paramount—through critical insight into go-to-market and positioning strategies, reform implications, and clinical value requirements.

Vaccines

For over twenty years, Oliver Wyman has been at the forefront of the vaccine space, partnering with manufacturers, investor groups, private foundations, and global health institutions to develop differentiated answers to their strategic and operational questions.

Pharmaceuticals & Biotechnology

Oliver Wyman partners with leading pharmaceutical and biotechnology companies to address strategic issues pertaining to product innovation, licensing, development, and commercialization.

Health Insurance Payers

Oliver Wyman works with payer organizations across the U.S. to drive improvements in the quality and affordability of care.  Our integrated health management approach not only drives near-term performance, but also transformational change necessary in a post-reform world.

Healthcare Providers

Oliver Wyman collaborates with provider organizations seeking to establish leadership positions in health management.  We provide strategic advice and clinical expertise focused on improving the cost and quality of care by enhancing outcomes and aligning incentives.